Table 1.
Patient demographics and clinical characteristics
| DOT 0 to 3 months (N = 629) | DOT 3 to 6 months (N = 244) | DOT over 6 months (N = 285) | |
|---|---|---|---|
| Age, mean (SD) [median] | 71.9 (9.7) [72.0] | 71.7 (11.2) [72.0] | 73.4 (8.5) [73.0] |
| Gender, female, n (%)1 | 307 (48.8) | 131 (53.7) | 141 (49.5) |
| Region, n (%) | |||
| South | 369 (58.7) | 145 (59.4) | 160 (56.1) |
| Midwest | 174 (27.7) | 69 (28.3) | 89 (31.2) |
| Northeast | 16 (2.5) | 4 (1.6) | 6 (2.1) |
| West | 70 (11.1) | 26 (10.7) | 30 (10.5) |
| Race/ethnicity, n (%) | |||
| White | 498 (79.2) | 191 (78.3) | 218 (76.5) |
| Black | 72 (11.4) | 21 (8.6) | 48 (16.8) |
| Hispanic | 4 (0.6) | 5 (2.0) | 0 (0.0) |
| Other | 11 (1.7) | 7 (2.9) | 2 (0.7) |
| Unknown | 44 (7.0) | 20 (8.2) | 17 (6.0) |
| Time from cancer to first VTE, n (%) | |||
| Less than 6 months | 349 (55.5) | 126 (51.6) | 135 (47.4) |
| 6 months to 1 year | 79 (12.6) | 31 (12.7) | 45 (15.8) |
| More than 1 year | 201 (32.0) | 87 (35.7) | 105 (36.8) |
| Type of index VTE, n (%) | |||
| PE | 159 (25.3) | 57 (23.4) | 82 (28.8) |
| DVT | 389 (61.8) | 164 (67.2) | 152 (53.3) |
| PE and DVT | 81 (12.9) | 23 (9.4) | 51 (17.9) |
| Type of anticoagulant therapy, n (%) | |||
| LMWH | 293 (46.6) | 49 (20.1) | 34 (11.9) |
| Warfarin | 185 (29.4) | 119 (48.8) | 169 (59.3) |
| Rivaroxaban | 151 (24.0) | 76 (31.1) | 82 (28.8) |
| Type of primary cancer2, n (%) | |||
| Solid cancer | 558 (88.7) | 212 (86.9) | 251 (88.1) |
| Lung | 106 (16.9) | 27 (11.1) | 36 (12.6) |
| Prostate | 69 (11.0) | 37 (15.2) | 40 (14.0) |
| Breast | 69 (11.0) | 35 (14.3) | 50 (17.5) |
| Colorectal | 78 (12.4) | 33 (13.5) | 40 (14.0) |
| Other solid cancer | 236 (38) | 80 (32.8) | 85 (29.8) |
| Hematologic cancer | 73 (11.6) | 34 (13.9) | 36 (12.6) |
| Risk for VTE | |||
| Very high risk3 | 56 (8.9) | 11 (4.5) | 10 (3.5) |
| High risk4 | 214 (34.0) | 73 (29.9) | 90 (31.6) |
| Antineoplastic use at baseline5, n (%) | 87 (13.8) | 42 (17.2) | 41 (14.4) |
| Quan-Charlson comorbidity index5, mean (SD) [median] | 4.8 (3.1) [5.0] | 4.7 (2.7) [5.0] | 4.4 (2.9) [4.0] |
| Selected baseline comorbidities5, n (%) | |||
| Hypertension | 435 (69.2) | 184 (75.4) | 214 (75.1) |
| COPD | 196 (31.2) | 60 (24.6) | 72 (25.3) |
| Diabetes | 172 (27.3) | 73 (29.9) | 91 (31.9) |
| Congestive heart failure | 92 (14.6) | 34 (13.9) | 35 (12.3) |
| Liver diseases | 98 (15.6) | 43 (17.6) | 26 (9.1) |
| Obesity | 94 (14.9) | 34 (13.9) | 39 (13.7) |
| Atrial fibrillation/flutter | 46 (7.3) | 17 (7.0) | 13 (4.6) |
| Stroke/TIA | 26 (4.1) | 6 (2.5) | 19 (6.7) |
SD, standard deviation; VTE, venous thromboembolism; DVT, deep venous thrombosis; PE, pulmonary embolism; COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack; LMWH, low-molecular-weight heparin
1The denominator of all percents is the respective cohort
2Not mutually exclusive
3Stomach, pancreas, or brain tumor
4Lung, lymphoma, gynecologic, bladder, testicular, or renal cancer
5Evaluated during the 6-month baseline period